Dr. Gregory Evans -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Gregory Evans, a Nephrology physician based in Worcester, MA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Gregory Evans has received $24,502.40 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Gregory Evans has received a total of $24,502.40 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $24,502.40 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Gregory Evans's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Consulting Fees$24,502.40Advisory board participation, clinical consulting, and expert opinion services

The largest payment category for Dr. Gregory Evans is Consulting Fees, accounting for 100% ($24,502.40) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Gregory Evans. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
AstraZeneca$24,502.401

Dr. Gregory Evans has a financial relationship with AstraZeneca, receiving $24,502.40 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Gregory Evans's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Gregory Evans has received $24.5K across 1 pharmaceutical payments as a Nephrology physician in Worcester, MA. Top paying companies include AstraZeneca ($24.5K). The physician received a single payment of $24,502 in 2024. This payment constituted 100% of the total reported amount, indicating high concentration from a single source. The payment was categorized as 'consulting' and originated from AstraZeneca.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Gregory Evans is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may want to ask their Nephrologist about any significant consulting relationships they have with pharmaceutical companies, especially if those companies produce medications relevant to their treatment. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Gregory Evans Compares to Other Nephrology Physicians

For a Nephrologist, this single, large consulting payment from AstraZeneca is notable, though it's difficult to compare without more data on typical consulting arrangements within the specialty.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Gregory Evans in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
AstraZeneca$24,502.40consultingN/A2024-09-21Not Assessed

Frequently Asked Questions About Dr. Gregory Evans's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Gregory Evans received?

Gregory Evans has received a total of $24.5K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Gregory Evans taking too much pharma money?

Gregory Evans has received $24.5K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Nephrology), the types of payments, and how they compare to peers. The largest payment category is consulting ($24.5K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Gregory Evans?

The top pharmaceutical companies paying Gregory Evans are: AstraZeneca ($24.5K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Gregory Evans receive?

Gregory Evans's payments by type: consulting: $24.5K. Consulting fees suggest active advisory roles with pharmaceutical companies.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Gregory Evans's payments compare to other Nephrology doctors?

To compare, look at the total amount ($24.5K), number of payments (1), and the types of payments received. Nephrology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Gregory Evans's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1736698137). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Gregory Evans's pharma payment profile?

The physician's payment profile is highly concentrated, with all reported funds coming from one company and for one type of service. Gregory Evans has received $24.5K in total pharma payments.

How does Gregory Evans compare to peers in Nephrology?

For a Nephrologist, this single, large consulting payment from AstraZeneca is notable, though it's difficult to compare without more data on typical consulting arrangements within the specialty.

Are Gregory Evans's pharma relationships typical for Nephrology?

The single, substantial payment suggests a significant engagement, possibly a consulting role or advisory board participation.

What should patients of Gregory Evans know about these payments?

Patients may want to ask their Nephrologist about any significant consulting relationships they have with pharmaceutical companies, especially if those companies produce medications relevant to their treatment.

What patterns are visible in Gregory Evans's payment history?

The data only reflects one payment, limiting the ability to identify broader trends or relationships with other pharmaceutical entities.

Understanding This Doctor Payment Report

This transparency report for Dr. Gregory Evans is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Gregory Evans's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Gregory Evans and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.